KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew R Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O'Malley, Deborah K Armstrong, Susana Banerjee, Jesús García-Donas, Elizabeth M Swisher, Coriolan Lebreton, Gottfried E Konecny, Iain A McNeish, Clare L Scott, Lara Maloney, Sandra Goble, Kevin K Lin, Robert L Coleman

Eur J Cancer 225 115584

PMID40580808
PMCIDPMC12687737
DOI10.1016/j.ejca.2025.115584
发表日期2025-06-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In ARIEL3, rucaparib maintenance significantly improved progression-free survival (PFS; primary endpoint) and long-term follow-up (LTFU) outcomes (including PFS2: time to disease progression on subsequent therapy or death) versus placebo in patients with recurrent, platinum-sensitive ovarian cancer. Here we report the final analysis of overall survival (OS; key secondary endpoint), LTFU outcomes, and safety. METHODS: OS and updated LTFU efficacy outcomes were analyzed (data cutoff date: April 4, 2022) across three nested populations (BRCA-mutated, homologous recombination deficient [HRD], and intention to treat [ITT]). RESULTS: Patients were randomized 2:1 to rucaparib (600 mg BID; n = 375) or placebo (n = 189). Median follow-up was 77.0 months. 168 patients in the placebo arm received subsequent treatment; of these, 77 (46 %) received a poly(ADP-ribose) polymerase inhibitor-containing treatment. Median OS from randomization post chemotherapy for rucaparib vs placebo was 45.9 vs 47.8 months (HR 0.83, 95 % CI 0.58-1.19) for the BRCA-mutated population; no OS benefit was found with rucaparib in the HRD and ITT populations. Median PFS2 for rucaparib vs placebo was 26.1 vs 18.4 months (HR 0.67, 95 % CI 0.48-0.94) for the BRCA-mutated population. Rucaparib numerically improved PFS2 and other LTFU outcomes versus placebo in the HRD and ITT populations. Safety was consistent with prior reports; myelodysplastic syndrome and/or acute myeloid leukemia occurred in 4 % and 3 % of patients in the rucaparib and placebo arms, respectively. CONCLUSIONS: OS was similar between treatment arms. PFS benefit with rucaparib was maintained through the subsequent therapy line. These data support rucaparib as maintenance treatment for recurrent ovarian carcinoma.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 2.

Fig. 2. Kaplan–Meier curves for OS in nested populations. Abbreviations: BRCA , BRCA1 or BRCA2 ; CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intention to treat; LOH, loss of heterozygosity; OS, overall survival. *Includes BRCA -mutated carcinoma and BRCA wild-type/LOH-high groups.

BRCA-mutated_carcinoma_population

OS

Fig. 2. · Panel BRCA-mutated_carcinoma_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel BRCA-mutated_carcinoma_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
HRD_carcinoma_population_

OS

Fig. 2. · Panel HRD_carcinoma_population_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel HRD_carcinoma_population_ 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
ITT_population

OS

Fig. 2. · Panel ITT_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel ITT_population 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
KM Figure3 个面板

Fig. 4.

Fig. 4. Kaplan–Meier curves for PFS2 in nested populations. Abbreviations: BRCA, BRCA1 or BRCA2; CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficient; ITT, intention to treat; LOH, loss of heterozygosity; PFS2, time to disease progression on subsequent therapy or death. *Includes BRCA-mutated carcinoma and BRCA wild-type/LOH-high carcinoma groups.

BRCA-mutated_carcinoma_population

PFS2

Fig. 4. · Panel BRCA-mutated_carcinoma_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel BRCA-mutated_carcinoma_population 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
HRD_carcinoma_population_

PFS2

Fig. 4. · Panel HRD_carcinoma_population_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel HRD_carcinoma_population_ 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
ITT_population

PFS2

Fig. 4. · Panel ITT_population

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel ITT_population 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Patient disposition (ITT population). Abbreviations: ITT, intention to treat; PARP, poly(ADP-ribose) polymerase; VEGF, vascular endothelial growth factor. *Among patients with disease that progressed and who started subsequent therapy. † Excludes regimens containing a PARP inhibitor. ‡ Includes use as maintenance or treatment. § Includes bevacizumab monotherapy or other VEGF inhibitor, immunotherapy, hormonal therapy, investigational treatment (unspecified), radiation, and hyperthermic intraperitoneal chemotherapy.
非 KM Figure
Fig. 3.Fig. 3. Timeline of long-term follow-up efficacy outcomes. Abbreviations: CFI, chemotherapy free interval; PD, progressive disease; PFS, progression-free survival; PFS2, time to disease progression on subsequent therapy or death; R, randomization; TFST, time to start of first subsequent therapy; TSST, time to start of second subsequent therapy.
非 KM Figure